nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—RAF1—breast cancer	0.143	0.328	CbGaD
Vemurafenib—BRAF—breast cancer	0.0991	0.227	CbGaD
Vemurafenib—ABCC1—breast cancer	0.0835	0.191	CbGaD
Vemurafenib—ABCG2—breast cancer	0.044	0.101	CbGaD
Vemurafenib—ABCC1—Idarubicin—breast cancer	0.0379	0.111	CbGbCtD
Vemurafenib—CYP2D6—breast cancer	0.0257	0.0588	CbGaD
Vemurafenib—CYP3A4—breast cancer	0.022	0.0504	CbGaD
Vemurafenib—ALB—breast cancer	0.0192	0.044	CbGaD
Vemurafenib—ABCC1—Mitoxantrone—breast cancer	0.0163	0.0478	CbGbCtD
Vemurafenib—CYP1A2—Anastrozole—breast cancer	0.0138	0.0405	CbGbCtD
Vemurafenib—ABCC1—Epirubicin—breast cancer	0.0132	0.0387	CbGbCtD
Vemurafenib—ABCC1—Paclitaxel—breast cancer	0.013	0.0381	CbGbCtD
Vemurafenib—ABCC1—Irinotecan—breast cancer	0.0128	0.0376	CbGbCtD
Vemurafenib—CYP1A2—Toremifene—breast cancer	0.0126	0.037	CbGbCtD
Vemurafenib—ABCC1—Vinblastine—breast cancer	0.0114	0.0335	CbGbCtD
Vemurafenib—ABCG2—Tamoxifen—breast cancer	0.0112	0.0328	CbGbCtD
Vemurafenib—ABCG2—Mitoxantrone—breast cancer	0.0109	0.032	CbGbCtD
Vemurafenib—CYP3A4—Exemestane—breast cancer	0.00953	0.028	CbGbCtD
Vemurafenib—ABCC1—Docetaxel—breast cancer	0.00939	0.0276	CbGbCtD
Vemurafenib—ABCG2—Paclitaxel—breast cancer	0.0087	0.0255	CbGbCtD
Vemurafenib—CYP2D6—Idarubicin—breast cancer	0.00861	0.0253	CbGbCtD
Vemurafenib—ABCG2—Irinotecan—breast cancer	0.00858	0.0252	CbGbCtD
Vemurafenib—ABCG2—Fluorouracil—breast cancer	0.00823	0.0242	CbGbCtD
Vemurafenib—ABCG2—Carboplatin—breast cancer	0.00818	0.024	CbGbCtD
Vemurafenib—CYP3A4—Letrozole—breast cancer	0.00811	0.0238	CbGbCtD
Vemurafenib—CYP3A4—Anastrozole—breast cancer	0.00722	0.0212	CbGbCtD
Vemurafenib—ABCC1—Doxorubicin—breast cancer	0.007	0.0206	CbGbCtD
Vemurafenib—ABCC1—Methotrexate—breast cancer	0.00678	0.0199	CbGbCtD
Vemurafenib—CYP3A4—Toremifene—breast cancer	0.00661	0.0194	CbGbCtD
Vemurafenib—ABCG2—Docetaxel—breast cancer	0.00629	0.0185	CbGbCtD
Vemurafenib—CYP3A4—Fulvestrant—breast cancer	0.00614	0.018	CbGbCtD
Vemurafenib—ALB—Irinotecan—breast cancer	0.00591	0.0174	CbGbCtD
Vemurafenib—ALB—Fluorouracil—breast cancer	0.00567	0.0167	CbGbCtD
Vemurafenib—CYP3A4—Thiotepa—breast cancer	0.00547	0.0161	CbGbCtD
Vemurafenib—CYP3A4—Ixabepilone—breast cancer	0.00501	0.0147	CbGbCtD
Vemurafenib—CYP3A4—Lapatinib—breast cancer	0.00482	0.0141	CbGbCtD
Vemurafenib—ABCG2—Doxorubicin—breast cancer	0.00469	0.0138	CbGbCtD
Vemurafenib—CYP1A2—Tamoxifen—breast cancer	0.00461	0.0135	CbGbCtD
Vemurafenib—ABCG2—Methotrexate—breast cancer	0.00454	0.0133	CbGbCtD
Vemurafenib—CYP2D6—Vinorelbine—breast cancer	0.0042	0.0123	CbGbCtD
Vemurafenib—CYP2D6—Tamoxifen—breast cancer	0.0038	0.0111	CbGbCtD
Vemurafenib—CYP3A4—Raloxifene—breast cancer	0.00365	0.0107	CbGbCtD
Vemurafenib—CYP1A2—Fluorouracil—breast cancer	0.00339	0.00996	CbGbCtD
Vemurafenib—ALB—Methotrexate—breast cancer	0.00313	0.00918	CbGbCtD
Vemurafenib—CYP3A4—Vinorelbine—breast cancer	0.00267	0.00785	CbGbCtD
Vemurafenib—CYP2D6—Vinblastine—breast cancer	0.00259	0.00761	CbGbCtD
Vemurafenib—CYP3A4—Tamoxifen—breast cancer	0.00241	0.00708	CbGbCtD
Vemurafenib—CYP3A4—Mitoxantrone—breast cancer	0.00235	0.00691	CbGbCtD
Vemurafenib—CYP3A4—Paclitaxel—breast cancer	0.00188	0.00551	CbGbCtD
Vemurafenib—RAF1—Topotecan—Irinotecan—breast cancer	0.00187	1	CbGdCrCtD
Vemurafenib—CYP3A4—Irinotecan—breast cancer	0.00185	0.00544	CbGbCtD
Vemurafenib—CYP3A4—Vinblastine—breast cancer	0.00165	0.00484	CbGbCtD
Vemurafenib—CYP2D6—Doxorubicin—breast cancer	0.00159	0.00467	CbGbCtD
Vemurafenib—CYP3A4—Docetaxel—breast cancer	0.00136	0.00399	CbGbCtD
Vemurafenib—RAF1—nipple—breast cancer	0.00108	0.0458	CbGeAlD
Vemurafenib—CYP3A4—Doxorubicin—breast cancer	0.00101	0.00297	CbGbCtD
Vemurafenib—BRAF—endometrium—breast cancer	0.000976	0.0415	CbGeAlD
Vemurafenib—BRAF—uterus—breast cancer	0.000899	0.0382	CbGeAlD
Vemurafenib—RAF1—embryo—breast cancer	0.000888	0.0378	CbGeAlD
Vemurafenib—BRAF—pituitary gland—breast cancer	0.000883	0.0375	CbGeAlD
Vemurafenib—BRAF—adipose tissue—breast cancer	0.000879	0.0374	CbGeAlD
Vemurafenib—BRAF—adrenal gland—breast cancer	0.000789	0.0335	CbGeAlD
Vemurafenib—ALB—mammary gland—breast cancer	0.000788	0.0335	CbGeAlD
Vemurafenib—BRAF—bone marrow—breast cancer	0.000763	0.0324	CbGeAlD
Vemurafenib—BRAF—female gonad—breast cancer	0.000735	0.0313	CbGeAlD
Vemurafenib—RAF1—epithelium—breast cancer	0.000725	0.0308	CbGeAlD
Vemurafenib—RAF1—skin of body—breast cancer	0.000689	0.0293	CbGeAlD
Vemurafenib—RAF1—endometrium—breast cancer	0.00065	0.0276	CbGeAlD
Vemurafenib—RAF1—uterus—breast cancer	0.000599	0.0255	CbGeAlD
Vemurafenib—RAF1—pituitary gland—breast cancer	0.000588	0.025	CbGeAlD
Vemurafenib—RAF1—adipose tissue—breast cancer	0.000586	0.0249	CbGeAlD
Vemurafenib—RAF1—female reproductive system—breast cancer	0.000538	0.0229	CbGeAlD
Vemurafenib—ABCC1—nipple—breast cancer	0.000538	0.0229	CbGeAlD
Vemurafenib—RAF1—adrenal gland—breast cancer	0.000525	0.0223	CbGeAlD
Vemurafenib—RAF1—bone marrow—breast cancer	0.000508	0.0216	CbGeAlD
Vemurafenib—RAF1—female gonad—breast cancer	0.00049	0.0208	CbGeAlD
Vemurafenib—BRAF—lymph node—breast cancer	0.000473	0.0201	CbGeAlD
Vemurafenib—RAF1—endocrine gland—breast cancer	0.000456	0.0194	CbGeAlD
Vemurafenib—ORM1—endometrium—breast cancer	0.000449	0.0191	CbGeAlD
Vemurafenib—Etoricoxib—CYP2D6—breast cancer	0.00044	0.371	CrCbGaD
Vemurafenib—CYP1A2—nipple—breast cancer	0.000429	0.0182	CbGeAlD
Vemurafenib—Etoricoxib—CYP3A4—breast cancer	0.000378	0.318	CrCbGaD
Vemurafenib—ORM1—female reproductive system—breast cancer	0.000372	0.0158	CbGeAlD
Vemurafenib—Etoricoxib—PTGS2—breast cancer	0.00037	0.311	CrCbGaD
Vemurafenib—ORM1—bone marrow—breast cancer	0.000351	0.0149	CbGeAlD
Vemurafenib—ABCC1—endometrium—breast cancer	0.000325	0.0138	CbGeAlD
Vemurafenib—ALB—adrenal gland—breast cancer	0.000318	0.0135	CbGeAlD
Vemurafenib—RAF1—lymph node—breast cancer	0.000315	0.0134	CbGeAlD
Vemurafenib—ORM1—endocrine gland—breast cancer	0.000315	0.0134	CbGeAlD
Vemurafenib—ABCC1—uterus—breast cancer	0.000299	0.0127	CbGeAlD
Vemurafenib—ABCC1—pituitary gland—breast cancer	0.000294	0.0125	CbGeAlD
Vemurafenib—ABCC1—adipose tissue—breast cancer	0.000293	0.0124	CbGeAlD
Vemurafenib—ABCG2—endometrium—breast cancer	0.000269	0.0114	CbGeAlD
Vemurafenib—ABCC1—adrenal gland—breast cancer	0.000263	0.0112	CbGeAlD
Vemurafenib—ABCG2—uterus—breast cancer	0.000248	0.0105	CbGeAlD
Vemurafenib—ABCC1—female gonad—breast cancer	0.000245	0.0104	CbGeAlD
Vemurafenib—ABCG2—pituitary gland—breast cancer	0.000243	0.0103	CbGeAlD
Vemurafenib—ABCG2—adipose tissue—breast cancer	0.000242	0.0103	CbGeAlD
Vemurafenib—ORM1—lymph node—breast cancer	0.000217	0.00924	CbGeAlD
Vemurafenib—ABCG2—adrenal gland—breast cancer	0.000217	0.00924	CbGeAlD
Vemurafenib—ABCG2—bone marrow—breast cancer	0.00021	0.00894	CbGeAlD
Vemurafenib—ABCG2—female gonad—breast cancer	0.000203	0.00862	CbGeAlD
Vemurafenib—ALB—lymph node—breast cancer	0.000191	0.00811	CbGeAlD
Vemurafenib—CYP1A2—endocrine gland—breast cancer	0.000181	0.00771	CbGeAlD
Vemurafenib—ABCC1—lymph node—breast cancer	0.000157	0.00669	CbGeAlD
Vemurafenib—CYP3A4—female reproductive system—breast cancer	0.000155	0.0066	CbGeAlD
Vemurafenib—CYP2D6—female reproductive system—breast cancer	0.000153	0.00649	CbGeAlD
Vemurafenib—CYP2D6—female gonad—breast cancer	0.000139	0.00591	CbGeAlD
Vemurafenib—CYP3A4—endocrine gland—breast cancer	0.000131	0.00558	CbGeAlD
Vemurafenib—ABCG2—lymph node—breast cancer	0.00013	0.00554	CbGeAlD
Vemurafenib—CYP2D6—endocrine gland—breast cancer	0.000129	0.00549	CbGeAlD
Vemurafenib—Dysgeusia—Capecitabine—breast cancer	4.52e-05	0.000445	CcSEcCtD
Vemurafenib—Dizziness—Vinorelbine—breast cancer	4.51e-05	0.000444	CcSEcCtD
Vemurafenib—Nervous system disorder—Paclitaxel—breast cancer	4.5e-05	0.000443	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Methotrexate—breast cancer	4.5e-05	0.000443	CcSEcCtD
Vemurafenib—Back pain—Capecitabine—breast cancer	4.47e-05	0.000439	CcSEcCtD
Vemurafenib—Diarrhoea—Thiotepa—breast cancer	4.46e-05	0.000439	CcSEcCtD
Vemurafenib—Skin disorder—Paclitaxel—breast cancer	4.46e-05	0.000439	CcSEcCtD
Vemurafenib—Body temperature increased—Mitoxantrone—breast cancer	4.45e-05	0.000438	CcSEcCtD
Vemurafenib—Body temperature increased—Irinotecan—breast cancer	4.45e-05	0.000438	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Doxorubicin—breast cancer	4.45e-05	0.000438	CcSEcCtD
Vemurafenib—Infestation NOS—Methotrexate—breast cancer	4.4e-05	0.000433	CcSEcCtD
Vemurafenib—Infestation—Methotrexate—breast cancer	4.4e-05	0.000433	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Methotrexate—breast cancer	4.36e-05	0.000429	CcSEcCtD
Vemurafenib—Vomiting—Vinorelbine—breast cancer	4.34e-05	0.000427	CcSEcCtD
Vemurafenib—Body temperature increased—Gemcitabine—breast cancer	4.34e-05	0.000426	CcSEcCtD
Vemurafenib—Dizziness—Thiotepa—breast cancer	4.31e-05	0.000424	CcSEcCtD
Vemurafenib—Rash—Vinorelbine—breast cancer	4.3e-05	0.000423	CcSEcCtD
Vemurafenib—Dermatitis—Vinorelbine—breast cancer	4.3e-05	0.000423	CcSEcCtD
Vemurafenib—Hypotension—Paclitaxel—breast cancer	4.29e-05	0.000422	CcSEcCtD
Vemurafenib—Headache—Vinorelbine—breast cancer	4.28e-05	0.000421	CcSEcCtD
Vemurafenib—Body temperature increased—Fluorouracil—breast cancer	4.26e-05	0.000419	CcSEcCtD
Vemurafenib—Eosinophilia—Doxorubicin—breast cancer	4.23e-05	0.000416	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Epirubicin—breast cancer	4.21e-05	0.000414	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Paclitaxel—breast cancer	4.18e-05	0.000412	CcSEcCtD
Vemurafenib—Weight decreased—Epirubicin—breast cancer	4.18e-05	0.000411	CcSEcCtD
Vemurafenib—Cough—Docetaxel—breast cancer	4.16e-05	0.000409	CcSEcCtD
Vemurafenib—Hypersensitivity—Mitoxantrone—breast cancer	4.15e-05	0.000408	CcSEcCtD
Vemurafenib—Hypersensitivity—Irinotecan—breast cancer	4.15e-05	0.000408	CcSEcCtD
Vemurafenib—Vomiting—Thiotepa—breast cancer	4.15e-05	0.000408	CcSEcCtD
Vemurafenib—Infestation—Epirubicin—breast cancer	4.12e-05	0.000405	CcSEcCtD
Vemurafenib—Infestation NOS—Epirubicin—breast cancer	4.12e-05	0.000405	CcSEcCtD
Vemurafenib—Rash—Thiotepa—breast cancer	4.11e-05	0.000404	CcSEcCtD
Vemurafenib—Dermatitis—Thiotepa—breast cancer	4.11e-05	0.000404	CcSEcCtD
Vemurafenib—Headache—Thiotepa—breast cancer	4.08e-05	0.000402	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Epirubicin—breast cancer	4.08e-05	0.000401	CcSEcCtD
Vemurafenib—Arthralgia—Docetaxel—breast cancer	4.06e-05	0.000399	CcSEcCtD
Vemurafenib—Myalgia—Docetaxel—breast cancer	4.06e-05	0.000399	CcSEcCtD
Vemurafenib—Nausea—Vinorelbine—breast cancer	4.05e-05	0.000399	CcSEcCtD
Vemurafenib—Asthenia—Mitoxantrone—breast cancer	4.04e-05	0.000397	CcSEcCtD
Vemurafenib—Asthenia—Irinotecan—breast cancer	4.04e-05	0.000397	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Epirubicin—breast cancer	4.03e-05	0.000397	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	4.03e-05	0.000397	CcSEcCtD
Vemurafenib—Cough—Capecitabine—breast cancer	4.03e-05	0.000396	CcSEcCtD
Vemurafenib—Decreased appetite—Paclitaxel—breast cancer	3.99e-05	0.000393	CcSEcCtD
Vemurafenib—Hypersensitivity—Fluorouracil—breast cancer	3.97e-05	0.000391	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Paclitaxel—breast cancer	3.96e-05	0.00039	CcSEcCtD
Vemurafenib—Fatigue—Paclitaxel—breast cancer	3.96e-05	0.000389	CcSEcCtD
Vemurafenib—Asthenia—Gemcitabine—breast cancer	3.93e-05	0.000387	CcSEcCtD
Vemurafenib—Arthralgia—Capecitabine—breast cancer	3.93e-05	0.000387	CcSEcCtD
Vemurafenib—Myalgia—Capecitabine—breast cancer	3.93e-05	0.000387	CcSEcCtD
Vemurafenib—Constipation—Paclitaxel—breast cancer	3.93e-05	0.000386	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	3.9e-05	0.000384	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Doxorubicin—breast cancer	3.9e-05	0.000384	CcSEcCtD
Vemurafenib—Anaphylactic shock—Docetaxel—breast cancer	3.89e-05	0.000383	CcSEcCtD
Vemurafenib—Pruritus—Gemcitabine—breast cancer	3.88e-05	0.000382	CcSEcCtD
Vemurafenib—Nausea—Thiotepa—breast cancer	3.87e-05	0.000381	CcSEcCtD
Vemurafenib—Infection—Docetaxel—breast cancer	3.87e-05	0.00038	CcSEcCtD
Vemurafenib—Weight decreased—Doxorubicin—breast cancer	3.86e-05	0.00038	CcSEcCtD
Vemurafenib—Diarrhoea—Mitoxantrone—breast cancer	3.85e-05	0.000379	CcSEcCtD
Vemurafenib—Diarrhoea—Irinotecan—breast cancer	3.85e-05	0.000379	CcSEcCtD
Vemurafenib—Nervous system disorder—Docetaxel—breast cancer	3.82e-05	0.000375	CcSEcCtD
Vemurafenib—Pruritus—Fluorouracil—breast cancer	3.82e-05	0.000375	CcSEcCtD
Vemurafenib—Infestation NOS—Doxorubicin—breast cancer	3.81e-05	0.000375	CcSEcCtD
Vemurafenib—Infestation—Doxorubicin—breast cancer	3.81e-05	0.000375	CcSEcCtD
Vemurafenib—Skin disorder—Docetaxel—breast cancer	3.78e-05	0.000372	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Doxorubicin—breast cancer	3.78e-05	0.000371	CcSEcCtD
Vemurafenib—Diarrhoea—Gemcitabine—breast cancer	3.75e-05	0.000369	CcSEcCtD
Vemurafenib—Infection—Capecitabine—breast cancer	3.74e-05	0.000368	CcSEcCtD
Vemurafenib—Erythema multiforme—Methotrexate—breast cancer	3.73e-05	0.000367	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Doxorubicin—breast cancer	3.73e-05	0.000367	CcSEcCtD
Vemurafenib—Dizziness—Irinotecan—breast cancer	3.72e-05	0.000366	CcSEcCtD
Vemurafenib—Nervous system disorder—Capecitabine—breast cancer	3.7e-05	0.000364	CcSEcCtD
Vemurafenib—Eye disorder—Methotrexate—breast cancer	3.69e-05	0.000363	CcSEcCtD
Vemurafenib—Diarrhoea—Fluorouracil—breast cancer	3.69e-05	0.000363	CcSEcCtD
Vemurafenib—Cardiac disorder—Methotrexate—breast cancer	3.66e-05	0.00036	CcSEcCtD
Vemurafenib—Skin disorder—Capecitabine—breast cancer	3.66e-05	0.00036	CcSEcCtD
Vemurafenib—Oedema peripheral—Epirubicin—breast cancer	3.64e-05	0.000358	CcSEcCtD
Vemurafenib—Hypotension—Docetaxel—breast cancer	3.64e-05	0.000358	CcSEcCtD
Vemurafenib—Connective tissue disorder—Epirubicin—breast cancer	3.63e-05	0.000357	CcSEcCtD
Vemurafenib—Body temperature increased—Paclitaxel—breast cancer	3.63e-05	0.000357	CcSEcCtD
Vemurafenib—Angiopathy—Methotrexate—breast cancer	3.58e-05	0.000352	CcSEcCtD
Vemurafenib—Vomiting—Irinotecan—breast cancer	3.58e-05	0.000352	CcSEcCtD
Vemurafenib—Vomiting—Mitoxantrone—breast cancer	3.58e-05	0.000352	CcSEcCtD
Vemurafenib—Dizziness—Fluorouracil—breast cancer	3.57e-05	0.000351	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methotrexate—breast cancer	3.56e-05	0.00035	CcSEcCtD
Vemurafenib—Rash—Mitoxantrone—breast cancer	3.55e-05	0.000349	CcSEcCtD
Vemurafenib—Rash—Irinotecan—breast cancer	3.55e-05	0.000349	CcSEcCtD
Vemurafenib—Dermatitis—Irinotecan—breast cancer	3.55e-05	0.000349	CcSEcCtD
Vemurafenib—Dermatitis—Mitoxantrone—breast cancer	3.55e-05	0.000349	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Docetaxel—breast cancer	3.55e-05	0.000349	CcSEcCtD
Vemurafenib—Chills—Methotrexate—breast cancer	3.54e-05	0.000348	CcSEcCtD
Vemurafenib—Headache—Mitoxantrone—breast cancer	3.53e-05	0.000347	CcSEcCtD
Vemurafenib—Headache—Irinotecan—breast cancer	3.53e-05	0.000347	CcSEcCtD
Vemurafenib—Hypotension—Capecitabine—breast cancer	3.52e-05	0.000346	CcSEcCtD
Vemurafenib—Erythema multiforme—Epirubicin—breast cancer	3.49e-05	0.000344	CcSEcCtD
Vemurafenib—Alopecia—Methotrexate—breast cancer	3.49e-05	0.000343	CcSEcCtD
Vemurafenib—Vomiting—Gemcitabine—breast cancer	3.49e-05	0.000343	CcSEcCtD
Vemurafenib—Rash—Gemcitabine—breast cancer	3.46e-05	0.00034	CcSEcCtD
Vemurafenib—Dermatitis—Gemcitabine—breast cancer	3.45e-05	0.00034	CcSEcCtD
Vemurafenib—Eye disorder—Epirubicin—breast cancer	3.45e-05	0.00034	CcSEcCtD
Vemurafenib—Malnutrition—Methotrexate—breast cancer	3.44e-05	0.000338	CcSEcCtD
Vemurafenib—Erythema—Methotrexate—breast cancer	3.44e-05	0.000338	CcSEcCtD
Vemurafenib—Headache—Gemcitabine—breast cancer	3.44e-05	0.000338	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Capecitabine—breast cancer	3.43e-05	0.000338	CcSEcCtD
Vemurafenib—Cardiac disorder—Epirubicin—breast cancer	3.43e-05	0.000337	CcSEcCtD
Vemurafenib—Vomiting—Fluorouracil—breast cancer	3.43e-05	0.000337	CcSEcCtD
Vemurafenib—Rash—Fluorouracil—breast cancer	3.4e-05	0.000334	CcSEcCtD
Vemurafenib—Dermatitis—Fluorouracil—breast cancer	3.4e-05	0.000334	CcSEcCtD
Vemurafenib—Decreased appetite—Docetaxel—breast cancer	3.38e-05	0.000333	CcSEcCtD
Vemurafenib—Hypersensitivity—Paclitaxel—breast cancer	3.38e-05	0.000333	CcSEcCtD
Vemurafenib—Headache—Fluorouracil—breast cancer	3.38e-05	0.000332	CcSEcCtD
Vemurafenib—Oedema peripheral—Doxorubicin—breast cancer	3.37e-05	0.000331	CcSEcCtD
Vemurafenib—Dysgeusia—Methotrexate—breast cancer	3.37e-05	0.000331	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Docetaxel—breast cancer	3.36e-05	0.000331	CcSEcCtD
Vemurafenib—Connective tissue disorder—Doxorubicin—breast cancer	3.36e-05	0.00033	CcSEcCtD
Vemurafenib—Fatigue—Docetaxel—breast cancer	3.36e-05	0.00033	CcSEcCtD
Vemurafenib—Angiopathy—Epirubicin—breast cancer	3.35e-05	0.00033	CcSEcCtD
Vemurafenib—Nausea—Mitoxantrone—breast cancer	3.34e-05	0.000329	CcSEcCtD
Vemurafenib—Nausea—Irinotecan—breast cancer	3.34e-05	0.000329	CcSEcCtD
Vemurafenib—Mediastinal disorder—Epirubicin—breast cancer	3.33e-05	0.000328	CcSEcCtD
Vemurafenib—Constipation—Docetaxel—breast cancer	3.33e-05	0.000327	CcSEcCtD
Vemurafenib—Back pain—Methotrexate—breast cancer	3.32e-05	0.000327	CcSEcCtD
Vemurafenib—Chills—Epirubicin—breast cancer	3.32e-05	0.000326	CcSEcCtD
Vemurafenib—Asthenia—Paclitaxel—breast cancer	3.29e-05	0.000324	CcSEcCtD
Vemurafenib—Decreased appetite—Capecitabine—breast cancer	3.28e-05	0.000322	CcSEcCtD
Vemurafenib—Alopecia—Epirubicin—breast cancer	3.27e-05	0.000321	CcSEcCtD
Vemurafenib—Nausea—Gemcitabine—breast cancer	3.26e-05	0.00032	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Capecitabine—breast cancer	3.25e-05	0.00032	CcSEcCtD
Vemurafenib—Fatigue—Capecitabine—breast cancer	3.25e-05	0.00032	CcSEcCtD
Vemurafenib—Pruritus—Paclitaxel—breast cancer	3.25e-05	0.00032	CcSEcCtD
Vemurafenib—Erythema multiforme—Doxorubicin—breast cancer	3.23e-05	0.000318	CcSEcCtD
Vemurafenib—Constipation—Capecitabine—breast cancer	3.22e-05	0.000317	CcSEcCtD
Vemurafenib—Malnutrition—Epirubicin—breast cancer	3.22e-05	0.000316	CcSEcCtD
Vemurafenib—Erythema—Epirubicin—breast cancer	3.22e-05	0.000316	CcSEcCtD
Vemurafenib—Nausea—Fluorouracil—breast cancer	3.2e-05	0.000315	CcSEcCtD
Vemurafenib—Eye disorder—Doxorubicin—breast cancer	3.2e-05	0.000314	CcSEcCtD
Vemurafenib—Cardiac disorder—Doxorubicin—breast cancer	3.17e-05	0.000312	CcSEcCtD
Vemurafenib—Dysgeusia—Epirubicin—breast cancer	3.15e-05	0.00031	CcSEcCtD
Vemurafenib—Diarrhoea—Paclitaxel—breast cancer	3.14e-05	0.000309	CcSEcCtD
Vemurafenib—Back pain—Epirubicin—breast cancer	3.11e-05	0.000306	CcSEcCtD
Vemurafenib—Angiopathy—Doxorubicin—breast cancer	3.1e-05	0.000305	CcSEcCtD
Vemurafenib—Mediastinal disorder—Doxorubicin—breast cancer	3.08e-05	0.000303	CcSEcCtD
Vemurafenib—Body temperature increased—Docetaxel—breast cancer	3.08e-05	0.000303	CcSEcCtD
Vemurafenib—Chills—Doxorubicin—breast cancer	3.07e-05	0.000302	CcSEcCtD
Vemurafenib—Dizziness—Paclitaxel—breast cancer	3.04e-05	0.000299	CcSEcCtD
Vemurafenib—Alopecia—Doxorubicin—breast cancer	3.02e-05	0.000297	CcSEcCtD
Vemurafenib—Cough—Methotrexate—breast cancer	3e-05	0.000295	CcSEcCtD
Vemurafenib—Body temperature increased—Capecitabine—breast cancer	2.98e-05	0.000293	CcSEcCtD
Vemurafenib—Malnutrition—Doxorubicin—breast cancer	2.98e-05	0.000293	CcSEcCtD
Vemurafenib—Erythema—Doxorubicin—breast cancer	2.98e-05	0.000293	CcSEcCtD
Vemurafenib—Arthralgia—Methotrexate—breast cancer	2.93e-05	0.000288	CcSEcCtD
Vemurafenib—Myalgia—Methotrexate—breast cancer	2.93e-05	0.000288	CcSEcCtD
Vemurafenib—Vomiting—Paclitaxel—breast cancer	2.92e-05	0.000287	CcSEcCtD
Vemurafenib—Dysgeusia—Doxorubicin—breast cancer	2.91e-05	0.000287	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	2.91e-05	0.000286	CcSEcCtD
Vemurafenib—Rash—Paclitaxel—breast cancer	2.9e-05	0.000285	CcSEcCtD
Vemurafenib—Dermatitis—Paclitaxel—breast cancer	2.89e-05	0.000285	CcSEcCtD
Vemurafenib—Back pain—Doxorubicin—breast cancer	2.88e-05	0.000283	CcSEcCtD
Vemurafenib—Headache—Paclitaxel—breast cancer	2.88e-05	0.000283	CcSEcCtD
Vemurafenib—Hypersensitivity—Docetaxel—breast cancer	2.87e-05	0.000282	CcSEcCtD
Vemurafenib—Cough—Epirubicin—breast cancer	2.81e-05	0.000276	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methotrexate—breast cancer	2.81e-05	0.000276	CcSEcCtD
Vemurafenib—Asthenia—Docetaxel—breast cancer	2.79e-05	0.000275	CcSEcCtD
Vemurafenib—Infection—Methotrexate—breast cancer	2.79e-05	0.000274	CcSEcCtD
Vemurafenib—Hypersensitivity—Capecitabine—breast cancer	2.78e-05	0.000273	CcSEcCtD
Vemurafenib—Pruritus—Docetaxel—breast cancer	2.75e-05	0.000271	CcSEcCtD
Vemurafenib—Nervous system disorder—Methotrexate—breast cancer	2.75e-05	0.000271	CcSEcCtD
Vemurafenib—Arthralgia—Epirubicin—breast cancer	2.74e-05	0.000269	CcSEcCtD
Vemurafenib—Myalgia—Epirubicin—breast cancer	2.74e-05	0.000269	CcSEcCtD
Vemurafenib—Nausea—Paclitaxel—breast cancer	2.73e-05	0.000268	CcSEcCtD
Vemurafenib—Skin disorder—Methotrexate—breast cancer	2.72e-05	0.000268	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	2.72e-05	0.000268	CcSEcCtD
Vemurafenib—Asthenia—Capecitabine—breast cancer	2.7e-05	0.000266	CcSEcCtD
Vemurafenib—Pruritus—Capecitabine—breast cancer	2.67e-05	0.000262	CcSEcCtD
Vemurafenib—Diarrhoea—Docetaxel—breast cancer	2.66e-05	0.000262	CcSEcCtD
Vemurafenib—Anaphylactic shock—Epirubicin—breast cancer	2.63e-05	0.000258	CcSEcCtD
Vemurafenib—Hypotension—Methotrexate—breast cancer	2.62e-05	0.000258	CcSEcCtD
Vemurafenib—Infection—Epirubicin—breast cancer	2.61e-05	0.000257	CcSEcCtD
Vemurafenib—Cough—Doxorubicin—breast cancer	2.6e-05	0.000255	CcSEcCtD
Vemurafenib—Diarrhoea—Capecitabine—breast cancer	2.58e-05	0.000254	CcSEcCtD
Vemurafenib—Nervous system disorder—Epirubicin—breast cancer	2.57e-05	0.000253	CcSEcCtD
Vemurafenib—Dizziness—Docetaxel—breast cancer	2.57e-05	0.000253	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Methotrexate—breast cancer	2.56e-05	0.000251	CcSEcCtD
Vemurafenib—Skin disorder—Epirubicin—breast cancer	2.55e-05	0.000251	CcSEcCtD
Vemurafenib—Arthralgia—Doxorubicin—breast cancer	2.53e-05	0.000249	CcSEcCtD
Vemurafenib—Myalgia—Doxorubicin—breast cancer	2.53e-05	0.000249	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	2.52e-05	0.000248	CcSEcCtD
Vemurafenib—Dizziness—Capecitabine—breast cancer	2.49e-05	0.000245	CcSEcCtD
Vemurafenib—Vomiting—Docetaxel—breast cancer	2.47e-05	0.000243	CcSEcCtD
Vemurafenib—Rash—Docetaxel—breast cancer	2.45e-05	0.000241	CcSEcCtD
Vemurafenib—Hypotension—Epirubicin—breast cancer	2.45e-05	0.000241	CcSEcCtD
Vemurafenib—Dermatitis—Docetaxel—breast cancer	2.45e-05	0.000241	CcSEcCtD
Vemurafenib—Decreased appetite—Methotrexate—breast cancer	2.44e-05	0.00024	CcSEcCtD
Vemurafenib—Headache—Docetaxel—breast cancer	2.44e-05	0.00024	CcSEcCtD
Vemurafenib—Anaphylactic shock—Doxorubicin—breast cancer	2.43e-05	0.000239	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Methotrexate—breast cancer	2.42e-05	0.000238	CcSEcCtD
Vemurafenib—Fatigue—Methotrexate—breast cancer	2.42e-05	0.000238	CcSEcCtD
Vemurafenib—Infection—Doxorubicin—breast cancer	2.41e-05	0.000237	CcSEcCtD
Vemurafenib—Vomiting—Capecitabine—breast cancer	2.4e-05	0.000236	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Epirubicin—breast cancer	2.39e-05	0.000235	CcSEcCtD
Vemurafenib—Nervous system disorder—Doxorubicin—breast cancer	2.38e-05	0.000234	CcSEcCtD
Vemurafenib—Rash—Capecitabine—breast cancer	2.38e-05	0.000234	CcSEcCtD
Vemurafenib—Dermatitis—Capecitabine—breast cancer	2.37e-05	0.000234	CcSEcCtD
Vemurafenib—Headache—Capecitabine—breast cancer	2.36e-05	0.000232	CcSEcCtD
Vemurafenib—Skin disorder—Doxorubicin—breast cancer	2.36e-05	0.000232	CcSEcCtD
Vemurafenib—Nausea—Docetaxel—breast cancer	2.31e-05	0.000227	CcSEcCtD
Vemurafenib—Decreased appetite—Epirubicin—breast cancer	2.28e-05	0.000224	CcSEcCtD
Vemurafenib—Hypotension—Doxorubicin—breast cancer	2.27e-05	0.000223	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Epirubicin—breast cancer	2.27e-05	0.000223	CcSEcCtD
Vemurafenib—Fatigue—Epirubicin—breast cancer	2.26e-05	0.000223	CcSEcCtD
Vemurafenib—Constipation—Epirubicin—breast cancer	2.24e-05	0.000221	CcSEcCtD
Vemurafenib—Nausea—Capecitabine—breast cancer	2.24e-05	0.00022	CcSEcCtD
Vemurafenib—Body temperature increased—Methotrexate—breast cancer	2.22e-05	0.000218	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Doxorubicin—breast cancer	2.21e-05	0.000218	CcSEcCtD
Vemurafenib—Decreased appetite—Doxorubicin—breast cancer	2.11e-05	0.000208	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Doxorubicin—breast cancer	2.1e-05	0.000206	CcSEcCtD
Vemurafenib—Fatigue—Doxorubicin—breast cancer	2.09e-05	0.000206	CcSEcCtD
Vemurafenib—Constipation—Doxorubicin—breast cancer	2.08e-05	0.000204	CcSEcCtD
Vemurafenib—Body temperature increased—Epirubicin—breast cancer	2.08e-05	0.000204	CcSEcCtD
Vemurafenib—Hypersensitivity—Methotrexate—breast cancer	2.07e-05	0.000203	CcSEcCtD
Vemurafenib—Asthenia—Methotrexate—breast cancer	2.01e-05	0.000198	CcSEcCtD
Vemurafenib—Pruritus—Methotrexate—breast cancer	1.98e-05	0.000195	CcSEcCtD
Vemurafenib—Hypersensitivity—Epirubicin—breast cancer	1.93e-05	0.00019	CcSEcCtD
Vemurafenib—Body temperature increased—Doxorubicin—breast cancer	1.92e-05	0.000189	CcSEcCtD
Vemurafenib—Diarrhoea—Methotrexate—breast cancer	1.92e-05	0.000189	CcSEcCtD
Vemurafenib—Asthenia—Epirubicin—breast cancer	1.88e-05	0.000185	CcSEcCtD
Vemurafenib—Pruritus—Epirubicin—breast cancer	1.86e-05	0.000183	CcSEcCtD
Vemurafenib—Dizziness—Methotrexate—breast cancer	1.85e-05	0.000182	CcSEcCtD
Vemurafenib—Diarrhoea—Epirubicin—breast cancer	1.8e-05	0.000177	CcSEcCtD
Vemurafenib—Hypersensitivity—Doxorubicin—breast cancer	1.79e-05	0.000176	CcSEcCtD
Vemurafenib—Vomiting—Methotrexate—breast cancer	1.78e-05	0.000175	CcSEcCtD
Vemurafenib—Rash—Methotrexate—breast cancer	1.77e-05	0.000174	CcSEcCtD
Vemurafenib—Dermatitis—Methotrexate—breast cancer	1.77e-05	0.000174	CcSEcCtD
Vemurafenib—Headache—Methotrexate—breast cancer	1.76e-05	0.000173	CcSEcCtD
Vemurafenib—Asthenia—Doxorubicin—breast cancer	1.74e-05	0.000171	CcSEcCtD
Vemurafenib—Dizziness—Epirubicin—breast cancer	1.74e-05	0.000171	CcSEcCtD
Vemurafenib—Pruritus—Doxorubicin—breast cancer	1.72e-05	0.000169	CcSEcCtD
Vemurafenib—Vomiting—Epirubicin—breast cancer	1.67e-05	0.000164	CcSEcCtD
Vemurafenib—Nausea—Methotrexate—breast cancer	1.67e-05	0.000164	CcSEcCtD
Vemurafenib—Diarrhoea—Doxorubicin—breast cancer	1.66e-05	0.000163	CcSEcCtD
Vemurafenib—Rash—Epirubicin—breast cancer	1.66e-05	0.000163	CcSEcCtD
Vemurafenib—Dermatitis—Epirubicin—breast cancer	1.65e-05	0.000163	CcSEcCtD
Vemurafenib—Headache—Epirubicin—breast cancer	1.64e-05	0.000162	CcSEcCtD
Vemurafenib—Dizziness—Doxorubicin—breast cancer	1.61e-05	0.000158	CcSEcCtD
Vemurafenib—Nausea—Epirubicin—breast cancer	1.56e-05	0.000153	CcSEcCtD
Vemurafenib—Vomiting—Doxorubicin—breast cancer	1.54e-05	0.000152	CcSEcCtD
Vemurafenib—Rash—Doxorubicin—breast cancer	1.53e-05	0.000151	CcSEcCtD
Vemurafenib—Dermatitis—Doxorubicin—breast cancer	1.53e-05	0.000151	CcSEcCtD
Vemurafenib—Headache—Doxorubicin—breast cancer	1.52e-05	0.00015	CcSEcCtD
Vemurafenib—Nausea—Doxorubicin—breast cancer	1.44e-05	0.000142	CcSEcCtD
Vemurafenib—ALB—Metabolism—ITPR1—breast cancer	1.57e-06	1.67e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CD—breast cancer	1.55e-06	1.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—STAT3—breast cancer	1.55e-06	1.64e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF1—breast cancer	1.55e-06	1.64e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT2—breast cancer	1.55e-06	1.64e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—breast cancer	1.54e-06	1.64e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP3A4—breast cancer	1.54e-06	1.64e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CB—breast cancer	1.54e-06	1.63e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ALB—breast cancer	1.53e-06	1.63e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP17A1—breast cancer	1.53e-06	1.62e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—breast cancer	1.53e-06	1.62e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—MAPK3—breast cancer	1.52e-06	1.61e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP1B1—breast cancer	1.52e-06	1.61e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ABCB1—breast cancer	1.51e-06	1.6e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HRAS—breast cancer	1.51e-06	1.6e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ENO1—breast cancer	1.51e-06	1.6e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS1—breast cancer	1.51e-06	1.6e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	1.51e-06	1.6e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SRC—breast cancer	1.5e-06	1.59e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CD—breast cancer	1.49e-06	1.58e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HSP90AA1—breast cancer	1.49e-06	1.58e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—breast cancer	1.49e-06	1.58e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—TYMS—breast cancer	1.49e-06	1.57e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SRC—breast cancer	1.49e-06	1.57e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MAPK3—breast cancer	1.48e-06	1.57e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP2D6—breast cancer	1.48e-06	1.57e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—breast cancer	1.48e-06	1.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SERPINE1—breast cancer	1.47e-06	1.56e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SRC—breast cancer	1.47e-06	1.56e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PLA2G4A—breast cancer	1.47e-06	1.56e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NCOR1—breast cancer	1.47e-06	1.56e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTM1—breast cancer	1.47e-06	1.56e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NOS3—breast cancer	1.47e-06	1.56e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—breast cancer	1.47e-06	1.55e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—KRAS—breast cancer	1.46e-06	1.55e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NCOA2—breast cancer	1.46e-06	1.54e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—STAT3—breast cancer	1.45e-06	1.54e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NCOA1—breast cancer	1.45e-06	1.53e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—breast cancer	1.45e-06	1.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—STAT3—breast cancer	1.43e-06	1.52e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—STK11—breast cancer	1.43e-06	1.51e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP19A1—breast cancer	1.43e-06	1.51e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—STAT3—breast cancer	1.42e-06	1.51e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—FASN—breast cancer	1.41e-06	1.5e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—breast cancer	1.41e-06	1.49e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MED12—breast cancer	1.41e-06	1.49e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—DPYD—breast cancer	1.41e-06	1.49e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GPX1—breast cancer	1.41e-06	1.49e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOS3—breast cancer	1.41e-06	1.49e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—BCHE—breast cancer	1.41e-06	1.49e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP1A1—breast cancer	1.39e-06	1.48e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC5A5—breast cancer	1.39e-06	1.47e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALDOA—breast cancer	1.39e-06	1.47e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MAPK3—breast cancer	1.39e-06	1.47e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ERCC2—breast cancer	1.38e-06	1.46e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MAPK3—breast cancer	1.37e-06	1.45e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—KRAS—breast cancer	1.37e-06	1.45e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MAPK3—breast cancer	1.36e-06	1.44e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CB—breast cancer	1.36e-06	1.44e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MYC—breast cancer	1.35e-06	1.43e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NCOA3—breast cancer	1.35e-06	1.43e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—breast cancer	1.35e-06	1.42e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—breast cancer	1.34e-06	1.42e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC2A1—breast cancer	1.34e-06	1.42e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NQO1—breast cancer	1.34e-06	1.42e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PIK3CA—breast cancer	1.34e-06	1.42e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC2A2—breast cancer	1.34e-06	1.42e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—AKT1—breast cancer	1.34e-06	1.41e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MDM2—breast cancer	1.34e-06	1.41e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KRAS—breast cancer	1.33e-06	1.41e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MYC—breast cancer	1.33e-06	1.41e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTEN—breast cancer	1.33e-06	1.41e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—breast cancer	1.33e-06	1.41e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—COMT—breast cancer	1.33e-06	1.41e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RELA—breast cancer	1.32e-06	1.4e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MYC—breast cancer	1.32e-06	1.4e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTP1—breast cancer	1.32e-06	1.4e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—breast cancer	1.32e-06	1.4e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—breast cancer	1.32e-06	1.4e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ERBB2—breast cancer	1.32e-06	1.39e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	1.31e-06	1.39e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCG2—breast cancer	1.31e-06	1.39e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTR—breast cancer	1.31e-06	1.39e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CPT1A—breast cancer	1.31e-06	1.39e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP3A4—breast cancer	1.31e-06	1.39e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—breast cancer	1.3e-06	1.38e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HMOX1—breast cancer	1.3e-06	1.38e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	1.3e-06	1.38e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ITPR1—breast cancer	1.3e-06	1.38e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CB—breast cancer	1.3e-06	1.38e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MTOR—breast cancer	1.3e-06	1.38e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MTHFR—breast cancer	1.3e-06	1.38e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—breast cancer	1.29e-06	1.37e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP1B1—breast cancer	1.29e-06	1.36e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HPGDS—breast cancer	1.28e-06	1.36e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HBA1—breast cancer	1.28e-06	1.35e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HSP90AA1—breast cancer	1.26e-06	1.34e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PIK3CA—breast cancer	1.26e-06	1.33e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ABCB1—breast cancer	1.25e-06	1.32e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL8—breast cancer	1.25e-06	1.32e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KRAS—breast cancer	1.25e-06	1.32e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ACHE—breast cancer	1.25e-06	1.32e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTT1—breast cancer	1.25e-06	1.32e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HRAS—breast cancer	1.24e-06	1.31e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KRAS—breast cancer	1.23e-06	1.3e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TYMS—breast cancer	1.23e-06	1.3e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NCOA1—breast cancer	1.23e-06	1.3e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PIK3CA—breast cancer	1.22e-06	1.3e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KRAS—breast cancer	1.22e-06	1.29e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN1B—breast cancer	1.22e-06	1.29e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—breast cancer	1.22e-06	1.29e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NCOR1—breast cancer	1.21e-06	1.29e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PLA2G4A—breast cancer	1.21e-06	1.29e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTM1—breast cancer	1.21e-06	1.29e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—STK11—breast cancer	1.21e-06	1.28e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP19A1—breast cancer	1.21e-06	1.28e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CAV1—breast cancer	1.2e-06	1.27e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP3—breast cancer	1.19e-06	1.27e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2—breast cancer	1.19e-06	1.26e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—breast cancer	1.19e-06	1.26e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP17A1—breast cancer	1.18e-06	1.25e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTEN—breast cancer	1.17e-06	1.24e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ENO1—breast cancer	1.17e-06	1.24e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS1—breast cancer	1.17e-06	1.24e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HRAS—breast cancer	1.16e-06	1.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCND1—breast cancer	1.16e-06	1.23e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GPX1—breast cancer	1.16e-06	1.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—JUN—breast cancer	1.16e-06	1.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CTNNB1—breast cancer	1.15e-06	1.22e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP1A1—breast cancer	1.15e-06	1.22e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CA—breast cancer	1.14e-06	1.21e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.14e-06	1.21e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2D6—breast cancer	1.14e-06	1.21e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ERCC2—breast cancer	1.14e-06	1.21e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.13e-06	1.2e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HRAS—breast cancer	1.13e-06	1.2e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PIK3CA—breast cancer	1.13e-06	1.2e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—breast cancer	1.13e-06	1.2e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN1A—breast cancer	1.13e-06	1.19e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—COMT—breast cancer	1.12e-06	1.19e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NCOA2—breast cancer	1.12e-06	1.19e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTEN—breast cancer	1.12e-06	1.19e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PIK3CA—breast cancer	1.12e-06	1.19e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTP1—breast cancer	1.12e-06	1.18e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—breast cancer	1.11e-06	1.17e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HMOX1—breast cancer	1.1e-06	1.17e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ITPR1—breast cancer	1.1e-06	1.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK8—breast cancer	1.1e-06	1.16e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKT1—breast cancer	1.1e-06	1.16e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CG—breast cancer	1.09e-06	1.16e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—FASN—breast cancer	1.09e-06	1.15e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—BCHE—breast cancer	1.09e-06	1.15e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—breast cancer	1.08e-06	1.15e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MTHFR—breast cancer	1.07e-06	1.14e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC5A5—breast cancer	1.07e-06	1.14e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HRAS—breast cancer	1.06e-06	1.12e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ABCB1—breast cancer	1.06e-06	1.12e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HRAS—breast cancer	1.05e-06	1.11e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SRC—breast cancer	1.04e-06	1.1e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TYMS—breast cancer	1.04e-06	1.1e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HRAS—breast cancer	1.04e-06	1.1e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC2A1—breast cancer	1.04e-06	1.1e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NQO1—breast cancer	1.04e-06	1.1e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTM1—breast cancer	1.03e-06	1.09e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PLA2G4A—breast cancer	1.03e-06	1.09e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NCOR1—breast cancer	1.03e-06	1.09e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—AKT1—breast cancer	1.03e-06	1.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—breast cancer	1.01e-06	1.07e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—breast cancer	1.01e-06	1.07e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STAT3—breast cancer	1e-06	1.06e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—breast cancer	1e-06	1.06e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AKT1—breast cancer	1e-06	1.06e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—breast cancer	9.93e-07	1.05e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP1B1—breast cancer	9.92e-07	1.05e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CAV1—breast cancer	9.89e-07	1.05e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GPX1—breast cancer	9.84e-07	1.04e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP1A1—breast cancer	9.75e-07	1.03e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HSP90AA1—breast cancer	9.73e-07	1.03e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ERCC2—breast cancer	9.66e-07	1.02e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CD—breast cancer	9.59e-07	1.02e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK3—breast cancer	9.59e-07	1.02e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NCOA1—breast cancer	9.47e-07	1e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CA—breast cancer	9.39e-07	9.94e-06	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT1—breast cancer	9.35e-07	9.9e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP19A1—breast cancer	9.33e-07	9.88e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—STK11—breast cancer	9.33e-07	9.88e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MYC—breast cancer	9.33e-07	9.88e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—breast cancer	9.31e-07	9.86e-06	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT1—breast cancer	9.24e-07	9.79e-06	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT1—breast cancer	9.16e-07	9.7e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—breast cancer	9.12e-07	9.67e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTHFR—breast cancer	9.08e-07	9.62e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NOS3—breast cancer	9.06e-07	9.6e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CG—breast cancer	9.01e-07	9.54e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—COMT—breast cancer	8.67e-07	9.19e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTP1—breast cancer	8.63e-07	9.14e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KRAS—breast cancer	8.62e-07	9.13e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HMOX1—breast cancer	8.51e-07	9.02e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ITPR1—breast cancer	8.5e-07	9e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CAV1—breast cancer	8.38e-07	8.88e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CB—breast cancer	8.36e-07	8.86e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—breast cancer	8.29e-07	8.78e-06	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CA—breast cancer	8.26e-07	8.75e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCB1—breast cancer	8.17e-07	8.66e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TYMS—breast cancer	8.03e-07	8.5e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	8.01e-07	8.48e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTM1—breast cancer	7.93e-07	8.4e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NCOR1—breast cancer	7.93e-07	8.4e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLA2G4A—breast cancer	7.93e-07	8.4e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CD—breast cancer	7.92e-07	8.39e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CA—breast cancer	7.92e-07	8.39e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALB—breast cancer	7.82e-07	8.28e-06	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AKT1—breast cancer	7.67e-07	8.12e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—breast cancer	7.66e-07	8.12e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CG—breast cancer	7.63e-07	8.09e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GPX1—breast cancer	7.6e-07	8.05e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP1A1—breast cancer	7.52e-07	7.97e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NOS3—breast cancer	7.48e-07	7.92e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ERCC2—breast cancer	7.46e-07	7.9e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HRAS—breast cancer	7.33e-07	7.76e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTEN—breast cancer	7.23e-07	7.65e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—breast cancer	7.01e-07	7.43e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTHFR—breast cancer	7.01e-07	7.43e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CB—breast cancer	6.9e-07	7.31e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—breast cancer	6.84e-07	7.25e-06	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKT1—breast cancer	6.75e-07	7.15e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CD—breast cancer	6.71e-07	7.11e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALB—breast cancer	6.62e-07	7.02e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT1—breast cancer	6.47e-07	6.85e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CAV1—breast cancer	6.47e-07	6.85e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NOS3—breast cancer	6.34e-07	6.71e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTEN—breast cancer	5.97e-07	6.32e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CG—breast cancer	5.89e-07	6.24e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CB—breast cancer	5.85e-07	6.2e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—breast cancer	5.8e-07	6.14e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CD—breast cancer	5.18e-07	5.49e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALB—breast cancer	5.11e-07	5.42e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CA—breast cancer	5.1e-07	5.4e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTEN—breast cancer	5.05e-07	5.35e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NOS3—breast cancer	4.89e-07	5.18e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CB—breast cancer	4.51e-07	4.78e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—breast cancer	4.47e-07	4.74e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CA—breast cancer	4.21e-07	4.46e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKT1—breast cancer	4.16e-07	4.41e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTEN—breast cancer	3.9e-07	4.13e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CA—breast cancer	3.57e-07	3.78e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKT1—breast cancer	3.44e-07	3.64e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKT1—breast cancer	2.91e-07	3.09e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CA—breast cancer	2.75e-07	2.91e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKT1—breast cancer	2.25e-07	2.38e-06	CbGpPWpGaD
